title: [Effects of octreotide on small bowel obstructions in rats].
abstract: OBJECTIVE
  Gastrointestinal decompression by nasogastric or intestinal tubes developed in 1930s has been the only treatment modality for inoperable intestinal obstruction. We hypothesized that the octreotide, a potent inhibitor of intestinal secretion, has a therapeutic potential in intestinal obstruction.
  
  
  METHODS
  Forty Sprague-Dawley rats were randomly assigned to four groups. The rats were subjected to complete or partial ileal obstruction. The treated rats received octreotide (100 microgram/kg) while the controls received the same quantity of saline every 12 hours for 24 or 48 hours. After 24 or 48 hours, the volumes of the small bowel contents were measured. The volumes of supernatant and the concentrations of electrolytes in the small bowel contents after centrifugation were also analyzed. The ileal segments proximal to obstruction were harvested, fixed, and stained, and the pathological changes were evaluated with mucosal damage scores.
  
  
  RESULTS
  There were no statistical differences in the volume and the electrolyte composition of intestinal fluid among the 4 groups. In the 48 hour complete obstruction group, the octreotide-treated rats showed statistically lower mucosal damage scores than the control rats (p<0.05).
  
  
  CONCLUSIONS
  Octreotide exerts mucosal protecting effect on the complete intestinal obstruction rat model.
authors.affiliation: Department of Emergency Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Joon Ho
authors.initials: JH
authors.lastname: Cho
authors.forename: Hyung Goo
authors.initials: HG
authors.lastname: Kang
authors.forename: Seung Ho
authors.initials: SH
authors.lastname: Kim
authors.forename: Hahn Shick
authors.initials: HS
authors.lastname: Lee
authors.forename: Kyeong Ryong
authors.initials: KR
authors.lastname: Lee
authors.forename: Hae Youn
authors.initials: HY
authors.lastname: Kang
mesh_terms: D000818:Animals; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D007077:Ileal Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D007082:Ileum / Q000473:pathology; D007415:Intestinal Obstruction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015282:Octreotide / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D005765:Gastrointestinal Agents; D015282:Octreotide